The Next Frontier In Downstream Processing With The 3M™ Polisher ST
Source: 3M Biopharmaceutical Purification
Monoclonal antibodies (mAbs) and recombinant therapeutic proteins are the two largest biologics segments, comprising nearly 86.0% of the total biologics market in 2019. Producing these molecules consistently at a commercial scale is both complex and costly ($300-$400 Million).
3M™ Polisher ST technology offers a sand box approach that provides several advantages including the ability to anticipate process yield, product purity and quality.
access the Brochure!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
This website uses cookies to ensure you get the best experience on our website. Learn more